| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802769901011 | 276990101 | BYETTA INJ.SOL 5MCG/20μL (0,25MG/ML) BT x 1 PF PEN x1,2ML | 55.47 | 58.18 | 74.01 |
| 05/2018 | 2802769902018 | 276990201 | BYETTA INJ.SOL 10MCG/40μL(0,25MG/ML) BT x1 PF PEN x 2,4ML | 64.08 | 67.22 | 85.50 |
Indicated as adjunctive therapy to improve glycemic control in patients with Type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of both, but have not achieved adequate glycemic control.
Exenatide is a functional analog of the human incretin Glucagon-Like Peptide-1 (GLP-1). Incretins enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. The GLP-1 system increases insulin secretion only in the presence of elevated plasma glucose levels, avoiding inappropriately high insulin levels during fasting. The drug also moderates peak serum glucagon levels during hyperglycemic periods following meals, but does not interfere with glucagon release in response to hypoglycemia. Secondary effects of drug administration reduces the rate of gastric emptying and decreases food intake, mitigating the potential severity of hyperglycemic events after meals.
Effects of the overdoses included severe nausea, severe vomiting, and rapidly declining blood glucose concentrations.
Following subcutaneous administration to patients with type 2 diabetes, exenatide reaches median peak plasma concentrations in 2.1 hours.
Mean terminal half-life is 2.4 hours.
Nonclinical studies have shown that exenatide is predominantly eliminated by glomerular filtration with subsequent proteolytic degradation.
* 28.3 L
* Apparent cl=9.1 L/hr